{"filing":{"accession_number":"0001140361-26-036499","cik":"0000842023","ticker":"TECH","company_name":"BIO-TECHNE Corp","form":"8-K","filing_date":"2026-09-14","report_date":"2026-09-14","primary_document":"ef20081960_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/842023/000114036126036499/ef20081960_8k.htm"},"events":[{"id":33347,"run_id":30657,"accession_number":"0001140361-26-036499","anchor_item_number":"8.01","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"summary":"This Item 8.01 disclosure concerns a material acquisition—the merger of Bio-Techne with Merck KGaA's subsidiary—announced on June 25, 2026, with a shareholder vote scheduled for September 23, 2026. Although the Item is titled \"Other Events,\" the core substance is supplemental disclosure of merger-related litigation and amended proxy disclosures regarding the transaction's background, financial advisor opinion, and deal process. The filing updates the proxy statement to address shareholder litigation alleging proxy deficiencies, making this fundamentally a disclosure update tied to the ongoing M\u0026A transaction, not a separate event category.","company_name":"BIO-TECHNE Corp","ticker":"TECH","filing_date":"2026-09-14","form":"8-K","submitted_at":null,"items":[{"id":36771,"accession_number":"0001140361-26-036499","item_number":"8.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"This Item 8.01 disclosure concerns a material acquisition—the merger of Bio-Techne with Merck KGaA's subsidiary—announced on June 25, 2026, with a shareholder vote scheduled for September 23, 2026. Although the Item is titled \"Other Events,\" the core substance is supplemental disclosure of merger-related litigation and amended proxy disclosures regarding the transaction's background, financial advisor opinion, and deal process. The filing updates the proxy statement to address shareholder litigation alleging proxy deficiencies, making this fundamentally a disclosure update tied to the ongoing M\u0026A transaction, not a separate event category.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-14T20:50:47.300641+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":36771,"accession_number":"0001140361-26-036499","item_number":"8.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"This Item 8.01 disclosure concerns a material acquisition—the merger of Bio-Techne with Merck KGaA's subsidiary—announced on June 25, 2026, with a shareholder vote scheduled for September 23, 2026. Although the Item is titled \"Other Events,\" the core substance is supplemental disclosure of merger-related litigation and amended proxy disclosures regarding the transaction's background, financial advisor opinion, and deal process. The filing updates the proxy statement to address shareholder litigation alleging proxy deficiencies, making this fundamentally a disclosure update tied to the ongoing M\u0026A transaction, not a separate event category.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-14T20:50:47.300641+00:00","company_name":"BIO-TECHNE Corp","ticker":"TECH","filing_date":"2026-09-14"}]}